Lili Ji

The Nrf2-HMOX1 pathway as a therapeutic target for reversing cisplatin resistance in non-small cell lung cancer via inhibiting ferroptosis

Interplay between Nrf2 and ROS in regulating epithelial-mesenchymal transition: implications for cancer metastasis and therapy

Mild phototherapy mediated by IR780-Gd-OPN nanomicelles suppresses atherosclerotic plaque progression through the activation of the HSP27-regulated NF-κB pathway

[Research Progress of Nrf2 and Ferroptosis in Tumor Drug Resistance].

The <scp>NRF2</scp> antagonist <scp>ML385</scp> inhibits <scp>PI3K‐mTOR</scp> signaling and growth of lung squamous cell carcinoma cells

PIDD interaction with KEAP1 as a new mutation-independent mechanism to promote NRF2 stabilization and chemoresistance in NSCLC

High expression of PINK1 promotes proliferation and chemoresistance of NSCLC

DISC1 overexpression promotes non-small cell lung cancer cell proliferation

Overexpression of MYCN promotes proliferation of non-small cell lung cancer

Expression of far upstream element binding protein 1 in B-cell non-Hodgkin lymphoma is correlated with tumor growth and cell-adhesion mediated drug resistance

Resistance integrons: class 1, 2 and 3 integrons

Upregulated expression of ILF2 in non-small cell lung cancer is associated with tumor cell proliferation and poor prognosis

Far upstream element-binding protein 1 (FUBP1) is a potential c-Myc regulator in esophageal squamous cell carcinoma (ESCC) and its expression promotes ESCC progression

Interaction with CCNH/CDK7 facilitates CtBP2 promoting esophageal squamous cell carcinoma (ESCC) metastasis via upregulating epithelial-mesenchymal transition (EMT) progression

TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway

Cell adhesion down-regulates the expression of vacuolar protein sorting 4B (VPS4B) and contributes to drug resistance in multiple myeloma cells

Correlation of Nrf2, NQO1, MRP1, cmyc and p53 in colorectal cancer and their relationships to clinicopathologic features and survival.

Nrf2 ameliorates diabetic nephropathy progression by transcriptional repression of TGFβ1 through interactions with c-Jun and SP1

Transformer 2β (Tra2β/SFRS10) positively regulates the progression of NSCLC via promoting cell proliferation

Expression of small glutamine-rich TPR-containing protein A (SGTA) in Non-Hodgkin's Lymphomas promotes tumor proliferation and reverses cell adhesion-mediated drug resistance (CAM-DR)

Identification of Gem as a new candidate prognostic marker in hepatocellular carcinoma

Involvement of p29/SYF2/fSAP29/NTC31 in the progression of NSCLC via modulating cell proliferation

Upregulation of SYF2 in esophageal squamous cell carcinoma promotes tumor cell proliferation and predicts poor prognosis

Nrf2 Pathway Regulates Multidrug-Resistance-Associated Protein 1 in Small Cell Lung Cancer